These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33860927)

  • 21. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
    Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
    Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
    Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
    Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
    Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
    Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
    Giorgino F; Guerci B; Füchtenbusch M; Lebrec J; Boye K; Orsini Federici M; Heitmann E; Dib A; Yu M; Sapin H; García-Pérez LE
    Diabetes Obes Metab; 2023 Dec; 25(12):3465-3477. PubMed ID: 37700627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
    Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
    Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
    Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T
    Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
    Basson M; Ntais D; Ayyub R; Wright D; Lowin J; Chartier F; Roze S; Norrbacka K
    Diabetes Ther; 2018 Feb; 9(1):13-25. PubMed ID: 29134607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
    Boye KS; Lebrec J; Dib A; Heitmann E; Federici MO; Yu M; Sapin H; Barrett A; Guerci B; Giorgino F; Füchtenbusch M; García-Pérez LE
    Diabetes Obes Metab; 2023 Dec; 25(12):3453-3464. PubMed ID: 37712754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
    Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
    Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
    Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
    Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
    Inaishi J; Saisho Y
    Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.